• Press Release

Discovery May Lead to Targeted Melanoma Therapies

  • (June 17, 2017)

Melanoma patients with high levels of a protein that controls the expression of pro-growth genes are less likely to survive, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell.

The research team found that the protein, called H2A.Z.2, promotes the abnormal growth seen in melanoma cells as they develop into difficult-to-treat tumors. H2A.Z.2 is part of the chromosome structure that packages genes, and has the ability to switch them on off. Having high levels of this protein aberrantly activates growth-promoting genes in melanoma cells.

An emerging theory in cancer research is that abnormal growth may result not only from unfortunate, mutations in patients’ genes, but also from epigenetic mechanisms that turn genes on and off. In the current study, authors found that blocking the functions of H2A.Z.2, either alone or in combination with cancer therapies, effectively blocked tumor growth and killed melanoma cells.  

“Cancer is a disease consisting of both genetic and epigenetic changes,” said Emily Bernstein, PhD, Associate Professor of Oncological Sciences and Dermatology, the Icahn School of Medicine at Mount Sinai, and lead study author. “I believe that the study of epigenetic mechanisms may lead to the development of new approaches for molecular diagnosis and targeted treatments.”

“Here we show that the histone variant H2A.Z.2 drives melanoma progression by affecting chromatin structure,” said Bernstein. “This is the first study to identify a specific role for the histone variant H2A.Z.2 in any tumor type. Next, we need to better understand how to prevent H2A.Z.2 function in chromatin.”

Research has only “scratched the surface” of the epigenetic mechanisms involved in cancer, Bernstein said. Gaining insights will pave the way for the design of innovative therapeutic regimens in melanoma as well as in other cancer types, she said.

This study was a collaborative effort by researchers at the Tisch Cancer Institute at Mount Sinai; New York University Langone Medical Center, New York, NY; Ludwig-Maximilians University, Munich, Germany; and Max-Planck Institute for Biochemistry, Martinsried, Germany.

About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the "Honor Roll" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 "Best Hospitals" issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals."

For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.